Accessibility to plasma-derived medicinal products in Malaysia: The challenges faced by patients with inborn errors of immunity

Lim, Bruce Wee Diong and Amir Hamzah, Abdul Latiff * (2024) Accessibility to plasma-derived medicinal products in Malaysia: The challenges faced by patients with inborn errors of immunity. Asia Pacific Allergy, 14 (1). pp. 1-4. ISSN 2233-8268

Full text not available from this repository.
Official URL: http://dx.doi.org/10.5415/apallergy.00000000000001...

Abstract

Inborn errors of immunity (IEI) (also known as primary immunodeficiencies) is an umbrella term for a growing group of over 450 different disorders that are characterized by defects in some of the components of the immune system. IEI are chronic diseases of genetic origin that render individuals suffering from them susceptible to infections. The mainstay of treatments for most patients with IEI, that is, predominantly antibody deficiencies is immunoglobulin replacement therapy (IRT), which is commonly delivered intravenously. Immunoglobulin (IG) therapy contains antibodies to compensate for the defective immune system’s inability to produce them. Individuals with IEI need IRT regularly throughout their lives to help combat infections and prevent organ damage. Without IRT, they are in danger of suffering from morbidity, poor quality of life, and reduced life expectancy. In the last 20 years, the use of IG preparation has tripled and this is partly attributed to the growing awareness and improved diagnoses of IEI cases. IG preparations are also used for the treatment of other medical conditions including secondary immunodeficiencies and autoimmune diseases. As IG is derived from human plasma, there are concerns about the availability of supply, particularly to treat life-threatening conditions that cannot be improved with other medications. It is estimated that 75% to 80% of IEI patients do not have access to adequate IG therapy throughout the world. This concern of supply and other challenges faced by patients with IEI in Malaysia are described from the patients’ perspective.

Item Type: Article
Uncontrolled Keywords: immunoglobulin; immunoglobulin replacement therapy; inborn errors of immunity; plasma-derived plasma products; primary immunodeficiencies; Malaysia;
Subjects: Q Science > QR Microbiology
R Medicine > RC Internal medicine
Divisions: Others > Non Sunway Academics
Sunway University > University Centres > Sunway Centre for Planetary Health
Depositing User: Ms Yong Yee Chan
Date Deposited: 09 May 2024 01:23
Last Modified: 09 May 2024 01:23
URI: http://eprints.sunway.edu.my/id/eprint/2573

Actions (login required)

View Item View Item